BAXTER INTERNATIONAL INC FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $11.2B |
| Gross margin | 30.1% |
| Operating income | −$308.0M |
| Net income | −$957.0M |
| Diluted EPS | −$1.87 |
| Cash & equivalents | $2.0B |
| Total assets | $20.1B |
| Long-term debt | $9.4B |
Key takeaway
Baxter completed the sale of its Kidney Care business in January 2025, using proceeds to repay $3.81 billion of legacy indebtedness and generate interest expense savings.
🔒 4 more takeaways in the full analysis
Beneath the surface
The company recently slashed its quarterly dividend to just $0.01 per share (from $0.52 declared per share in aggregate for the year), an explicit signal of cash flow strain tied to its debt burden.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for BAX.
Read the full analysis free Free account · 5 full analyses included · no card required